AR053683A1 - Derivados de piperidina con actividad antibacteriana - Google Patents
Derivados de piperidina con actividad antibacterianaInfo
- Publication number
- AR053683A1 AR053683A1 ARP060100590A ARP060100590A AR053683A1 AR 053683 A1 AR053683 A1 AR 053683A1 AR P060100590 A ARP060100590 A AR P060100590A AR P060100590 A ARP060100590 A AR P060100590A AR 053683 A1 AR053683 A1 AR 053683A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- carbamoyl
- halo
- alkoxy
- alkanoyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Compuestos de formula (1) y sus sales aceptables para uso farmacéutico. Procesos para su preparacion, composiciones farmacéuticas que los contienen, su uso como medicamentos y su uso en el tratamiento de infecciones bacterianas. Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1), en donde: R1 se selecciona entre hidrogeno, nitro, hidroxi, halo, ciano, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, alcanoilo C1-4, alquilC1-4S(O)a, en donde a es entre 0 y 2 y cicloalquilo C3-6; en donde R1 puede estar opcionalmente sustituido sobre carbono por uno o más halo o ciclopropilo; R2 se selecciona entre hidrogeno, nitro, hidroxi, halo, ciano, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, alcanoilo C1-4, alquilC1-4S(O)a, en donde a es entre 0 y 2 y cicloalquilo C3-6; en donde R2 puede estar opcionalmente sustituido sobre carbono por uno o más halo o cicloalquilo C3-6; R3 se selecciona entre hidrogeno, nitro, hidroxi, halo, ciano, - C=N-OR', en donde R' es H o alquilo C1-4, alquilo C1-4, alcoxi C1-4, alquenilo C2-4, alquinilo C2-4, alcanoilo C1-4, alquilC1-4S(O)a, en donde a es entre 0 y 2 y cicloalquilo C3-6; en donde R3 puede estar opcionalmente sustituido sobre carbono por uno o más halo o cicloalquilo C3-6; W es -O-, -N(R6)- o -C(R7)(R8)-; X es un enlace directo, -CH2-, -C(O)- o -S(O)q- (en donde q es 1 o 2); el anillo A es carbociclilo o heterociclilo; en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido por un grupo seleccionado entre R9; R4 y R5 son sustituyentes sobre carbono y se seleccionan en forma independiente entre halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, sulfo, formilo, ureido, hidroxiiminometilo, alcoxiiminometilo C1-4, N-hidroxiformanido, hidrazino C1-4, hidrazinocarbonilo, N-hidroxiethanimidoilo, amino(hidroxiimino)metilo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoilo C1-4, alcanoiloxi C1-4, N-(alquilC1-4)amino, N,N-(alquilC1-4)2amino, alcanoilamino C1-4, N-(alquilC1-4)carbamoilo, N,N-(alquilC1-4) 2carbamoilo, N-(alcoxiC1-4)carbamoilo, N'-(alquilC1-4)ureido, N',N'-(alquilC1-4)2ureido, N-(alquilC1- 4)-N-(alcoxiC1-4)carbamoilo, alquilC1-4S(O)a en donde a es entre 0 y 2, alcoxicarbonilo C1-4, alcoxicarbonilamino C1-4, N-(alquilC1-4)sulfamoilo, N,N-(alquilC1-4) 2sulfamoilo, alquilsulfonilamino C1-4, alquilsulfonilaminocarbonilo C1-4, N'-(alquilC1- 4)hidrazinocarbonilo, N',N'-(alquilC1-4) 2hidrazinocarbonilo, carbociclil-R10- o heterociclil-R11-; en donde R4 y R5 en forma independiente entre sí pueden estar opcionalmente sustituidos sobre carbono por uno o más R12; y donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido por un grupo seleccionado entre R13; R6 R7 y R8 se seleccionan en forma independiente entre hidrogeno o C1-4 alquilo; n es 1-4; en donde los valores de R4 pueden ser iguales o diferentes; m es 0-4; en donde los valores de R5 pueden ser iguales o diferentes; R12 se selecciona entre azido, halo, nitro, ciano, hidroxi, trifluorometoxi, amino, carboxi, carbamoilo, mercapto, sulfamoilo, alquilo C1-4, alquenilo C2-4, alquinilo C2-4, alcoxi C1-4, alcanoilo C1-4, alcanoiloxi C1-4, N-(alquilC1-4)amino, N,N-(alquilC1-4)2amino, alcanoilamino C1-4, N-(alquilC1-4)carbamoilo, N,N-(alquilC1-4)2carbamoilo, alquilC1-4S(O)a, en donde a es entre 0 y 2, alcoxicarboniloC1-4, N-(alquilC1-4)sulfamoilo, N,N-(alquilC1-4)2sulfamoilo, alquilsulfonilamino C1-4, alcoxicarbonilamino C1-4, carbociclil-R14- o heterociclil-R15-; en donde R12 en forma independiente entre sí pueden estar opcionalmente sustituidos sobre carbono por uno o más R16; y en donde si dicho heterociclilo contiene una porcion -NH- dicho nitrogeno puede estar opcionalmente sustituido por un grupo seleccionado entre R17; R9, R13 y R17 se seleccionan en forma independiente entre alquilo C1-4, alcanoilo C1-4, alquilsulfonilo C1-4, alcoxicarbonilo C1-4, carbamoilo, N-(alquilC1-4)carbamoilo, N,N-(alquilC1-4)carbamoilo, bencilo, benciloxicarbonilo, benzoílo y fenilsulfonilo; R10, R11, R14 y R15 se seleccionan en forma independiente entre un enlace directo, -O-, -N(R18)-, -C(O)-, - N(R19)C(O)-, -C(O)N(R20)-, -S(O)p-, -SO2N(R21)- o -N(R22)SO2-; en donde R18, R19, R20, R21 y R22 se seleccionan en forma independiente entre hidrogeno o alquilo C1-4 y p es 0-2; R16 se selecciona entre halo, nitro, ciano, hidroxi, trifluorometoxi, trifluorometilo, amino, carboxi, carbamoilo, mercapto, sulfamoilo, metilo, etilo, etenilo, etinilo, metoxi, etoxi, acetilo, acetoxi, metilamino, etilamino, dimetilamino, dietilamino, N-metil-N- etilamino; acetilamino, N-metilcarbamoilo, N-etilcarbamoilo, N,N-dimetilcarbamoilo, N,N- dietilcarbamoilo, N-metil-N-etilcarbamoilo, metiltio, etiltio, metilsulfinilo, etilsulfinilo, mesilo, etilsulfonilo, metoxicarbonilo, etoxicarbonilo, N- metilsulfamoilo, N-etilsulfamoilo, N,N-dimetilsulfamoilo, N,N-dietilsulfalmoilo o N-metil-N-etilsulfamoilo; o una de sus sales aceptables para uso farmacéutico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65467005P | 2005-02-18 | 2005-02-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR053683A1 true AR053683A1 (es) | 2007-05-16 |
Family
ID=36218455
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP060100590A AR053683A1 (es) | 2005-02-18 | 2006-02-17 | Derivados de piperidina con actividad antibacteriana |
Country Status (22)
Country | Link |
---|---|
US (2) | US8399489B2 (es) |
EP (1) | EP1853586B1 (es) |
JP (4) | JP4058106B2 (es) |
KR (2) | KR101422432B1 (es) |
CN (1) | CN101163693B (es) |
AR (1) | AR053683A1 (es) |
AU (1) | AU2006215399B2 (es) |
BR (1) | BRPI0607756A2 (es) |
CA (1) | CA2598423C (es) |
ES (1) | ES2430569T3 (es) |
HK (1) | HK1114376A1 (es) |
IL (1) | IL185306A (es) |
MX (1) | MX2007010072A (es) |
NO (1) | NO20074703L (es) |
NZ (1) | NZ561613A (es) |
RU (1) | RU2424240C2 (es) |
SA (1) | SA06270020B1 (es) |
TW (1) | TWI402263B (es) |
UA (1) | UA94901C2 (es) |
UY (1) | UY29384A1 (es) |
WO (1) | WO2006087543A1 (es) |
ZA (1) | ZA200706920B (es) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
AU2006215399B2 (en) * | 2005-02-18 | 2010-12-09 | Astrazeneca Ab | Antibacterial piperidine derivatives |
EP1861396A1 (en) * | 2005-03-04 | 2007-12-05 | AstraZeneca AB | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
WO2008020229A2 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
TW200819437A (en) * | 2006-08-17 | 2008-05-01 | Astrazeneca Ab | Chemical compounds |
WO2008020227A2 (en) * | 2006-08-17 | 2008-02-21 | Astrazeneca Ab | Antibacterial pyrrolecarboxamides |
KR20090106604A (ko) | 2007-01-12 | 2009-10-09 | 아스텔라스세이야쿠 가부시키가이샤 | 축합 피리딘 화합물 |
TW200906412A (en) * | 2007-06-12 | 2009-02-16 | Astrazeneca Ab | Piperidine compounds and uses thereof |
WO2009081789A1 (ja) * | 2007-12-26 | 2009-07-02 | Banyu Pharmaceutical Co., Ltd. | スルホニル置換六員環誘導体 |
TWI498115B (zh) * | 2007-12-27 | 2015-09-01 | Daiichi Sankyo Co Ltd | 咪唑羰基化合物 |
CA2732618A1 (en) * | 2008-07-30 | 2010-02-04 | Ranbaxy Laboratories Limited | Pyrrole carboxylic acid derivatives as antibacterial agents |
AU2009303335B2 (en) * | 2008-10-09 | 2016-05-19 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
US8071605B2 (en) | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
TW201026694A (en) | 2008-12-12 | 2010-07-16 | Astrazeneca Ab | Compound 468 |
JO3346B1 (ar) | 2008-12-22 | 2019-03-13 | Chemocentryx Inc | مواد مضادة C5aR |
JP5756457B2 (ja) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2調節剤、治療組成物および関連する使用方法 |
ES2619557T3 (es) | 2009-05-04 | 2017-06-26 | Agios Pharmaceuticals, Inc. | Activadores de PKM2 para uso en el tratamiento del cáncer |
TW201102065A (en) | 2009-05-29 | 2011-01-16 | Astrazeneca Ab | Heterocyclic urea derivatives and methods of use thereof |
EP2448581B1 (en) | 2009-06-29 | 2016-12-07 | Agios Pharmaceuticals, Inc. | Therapeutic compositions and related methods of use |
SG10201403696UA (en) | 2009-06-29 | 2014-10-30 | Agios Pharmaceuticals Inc | Therapeutic compounds and compositions |
WO2011024004A1 (en) | 2009-08-26 | 2011-03-03 | Astrazeneca Ab | Heterocyclic urea derivatives useful for treatment of bacterial infection |
JP2013525438A (ja) | 2010-04-29 | 2013-06-20 | アメリカ合衆国 | ヒトピルビン酸キナーゼ活性剤 |
WO2011163640A1 (en) | 2010-06-24 | 2011-12-29 | Chemocentryx, Inc. | C5ar antagonists |
WO2012030944A2 (en) | 2010-09-01 | 2012-03-08 | Ambit Biosciences Corporation | Quinoline and isoquinoline compounds and methods of use thereof |
JP5837091B2 (ja) | 2010-12-17 | 2015-12-24 | アジオス ファーマシューティカルズ, インコーポレイテッド | ピルビン酸キナーゼm2(pkm2)調節剤としての新規n−(4−(アゼチジン−1−カルボニル)フェニル)−(ヘテロ−)アリールスルホンアミド誘導体 |
MX336022B (es) | 2010-12-21 | 2016-01-06 | Agios Pharmaceuticals Inc | Activadores de pkm2 bicíclicos. |
TWI549947B (zh) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | 治療化合物及組成物 |
EP2511263A1 (en) | 2011-04-14 | 2012-10-17 | Phenex Pharmaceuticals AG | Pyrrolo sulfonamide compounds for modulation of orphan nuclear receptor RAR-related orphan receptor-gamma (RORgamma, NR1F3) activity and for the treatment of chronic inflammatory and autoimmune diseases |
WO2012143081A1 (en) | 2011-04-18 | 2012-10-26 | Merck Patent Gmbh | Conjugated polymers |
BR112013028422B8 (pt) | 2011-05-03 | 2022-01-11 | Agios Pharmaceuticals Inc | Ativadores de piruvato cinase para uso em terapia |
WO2013084241A1 (en) * | 2011-12-09 | 2013-06-13 | Cadila Healthcare Limited | Compounds as inhibitors of renin |
JP6073931B2 (ja) * | 2012-02-02 | 2017-02-01 | アクテリオン ファーマシューティカルズ リミテッドActelion Pharmaceuticals Ltd | 4−(ベンゾイミダゾール−2−イル)−チアゾール化合物及び関連するアザ誘導体 |
AU2014295123B2 (en) * | 2013-07-22 | 2018-08-02 | Idorsia Pharmaceuticals Ltd | 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives |
CN106715454B (zh) | 2014-07-24 | 2020-06-16 | 格雷斯公司 | 烟酰胺核苷的结晶形式 |
AU2015324111B2 (en) | 2014-09-29 | 2021-04-01 | Chemocentryx, Inc. | Processes and intermediates in the preparation of C5aR antagonists |
BR112017019409A2 (pt) | 2015-03-09 | 2018-04-24 | Grace W R & Co | forma cristalina de ribosídeo de nicotinamida |
LT3307271T (lt) | 2015-06-11 | 2023-10-25 | Agios Pharmaceuticals, Inc. | Piruvatkinazės aktyvatorių panaudojimo būdai |
CN105067814A (zh) * | 2015-07-24 | 2015-11-18 | 中国科学院成都生物研究所 | 解旋酶水解atp活性测定方法 |
KR20180054650A (ko) | 2015-09-30 | 2018-05-24 | 다이이찌 산쿄 가부시키가이샤 | 히드록시알킬 티아디아졸 유도체 |
CN108601790A (zh) | 2016-01-14 | 2018-09-28 | 凯莫森特里克斯股份有限公司 | C3肾小球病的治疗方法 |
SG11201900633XA (en) * | 2016-07-28 | 2019-02-27 | Idorsia Pharmaceuticals Ltd | Piperidine cxcr7 receptor modulators |
CA3056571C (en) | 2017-03-14 | 2021-11-23 | Daiichi Sankyo Company, Limited | N-phosphonoxymethyl prodrugs of hydroxyalkyl thiadiazole derivatives |
RU2019133662A (ru) | 2017-03-24 | 2021-04-26 | Тайсо Фармасьютикал Ко., Лтд. | Производное 2(1h)-хинолинона |
CN112020363A (zh) | 2017-12-22 | 2020-12-01 | 益力舒健康公司 | 烟酰胺核苷氯化物的结晶形式 |
US11339148B2 (en) | 2018-01-26 | 2022-05-24 | Idorsia Pharmaceuticals Ltd. | Crystalline forms of the CXCR7 receptor antagonist (3S,4S)-1-Cyclopropylmethyl-4-{[5-(2,4-difluoro-phenyl)-isoxazole-3-carbonyl]-amino}-piperidine-3-carboxylic acid (1-pyrimidin-2-yl-cyclopropyl)-amide |
EP3847172A1 (en) | 2018-09-03 | 2021-07-14 | Univerza v Ljubljani | New class of dna gyrase and/or topoisomerase iv inhibitors with activity against gram-positive and gram-negative bacteria |
WO2022129327A1 (en) | 2020-12-17 | 2022-06-23 | Univerza V Ljubljani | New n-phenylpyrrolamide inhibitors of dna gyrase and topoisomerase iv with antibacterial activity |
CN115466246B (zh) * | 2021-06-11 | 2024-02-06 | 中国医学科学院药物研究所 | 吡咯酰哌啶胺类化合物及其用途 |
CN115612309B (zh) * | 2022-10-14 | 2023-07-21 | 浙江博澳新材料股份有限公司 | 一种双杂环双酯基偶氮分散染料及其制备方法 |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL23847A (en) | 1964-08-07 | 1969-02-27 | Merck & Co Inc | Benzimidazoles useful as antifungals |
US4046775A (en) * | 1973-04-11 | 1977-09-06 | Sterling Drug Inc. | 4,5-Dihalopyrrole-2-carboxamides |
US3963480A (en) * | 1973-04-11 | 1976-06-15 | Sterling Drug Inc. | Herbicidal pyrrole-2-carboxamides |
US4912109A (en) * | 1987-02-02 | 1990-03-27 | Boc, Inc. | N-heterocyclic-N-(4-piperidinyl) amides and pharmaceutical compositions and methods employing such compounds |
US4791112A (en) * | 1987-02-02 | 1988-12-13 | The Boc Group, Inc. | N-heterocyclic-N-(4-piperidyl)amides and pharmaceutical compositions and methods employing such compounds |
US5739135A (en) * | 1993-09-03 | 1998-04-14 | Bristol-Myers Squibb Company | Inhibitors of microsomal triglyceride transfer protein and method |
FR2766488B1 (fr) | 1997-07-23 | 2000-02-18 | Hoechst Marion Roussel Inc | Nouveaux derives aromatiques substitues par un ribose, leur procede de preparation et leur application comme medicaments |
AU2437900A (en) * | 1999-01-20 | 2000-08-07 | Smithkline Beecham Plc | Piperidinylquinolines as protein tyrosine kinase inhibitors |
US7629360B2 (en) * | 1999-05-07 | 2009-12-08 | Celgene Corporation | Methods for the treatment of cachexia and graft v. host disease |
JP2003104971A (ja) | 1999-08-12 | 2003-04-09 | Wakunaga Pharmaceut Co Ltd | 新規アニリド誘導体又はその塩及びこれを含有する医薬 |
EP1251849A1 (en) | 2000-01-18 | 2002-10-30 | Vertex Pharmaceuticals Incorporated | Gyrase inhibitors and uses thereof |
CN1230166C (zh) | 2000-01-18 | 2005-12-07 | 沃泰克斯药物股份有限公司 | 回旋酶抑制剂及其用途 |
TWI284639B (en) | 2000-01-24 | 2007-08-01 | Shionogi & Co | A compound having thrombopoietin receptor agonistic effect |
AU2001269821A1 (en) | 2000-06-15 | 2001-12-24 | Barbara Chen | Cycloalkyl alkanoic acids as integrin receptor antagonists |
US6964966B2 (en) | 2001-04-25 | 2005-11-15 | Wockhardt Limited | Generation triple-targeting, chiral, broad-spectrum antimicrobial 7-substituted piperidino-quinolone carboxylic acid derivatives, their preparation, compositions and use as medicaments |
DOP2002000386A (es) | 2001-05-30 | 2002-12-15 | Warner Lambert Co | Agentes antibacterianos |
EP1431267A4 (en) | 2001-08-09 | 2004-12-22 | Ono Pharmaceutical Co | COMPOUNDS DERIVED FROM CARBOXYLIC ACID AND MEDICAMENTS COMPRISING SUCH COMPOUNDS AS ACTIVE INGREDIENT |
AU2002356689B2 (en) | 2001-12-05 | 2008-05-15 | Sanofi-Aventis Deutschland Gmbh | Substituted 4-phenyltetrahydroisoquinolines, method for the production thereof, the use thereof as medicaments, in addition to a medicament containing same |
AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
EP1486490A1 (en) | 2002-02-28 | 2004-12-15 | Takeda Chemical Industries, Ltd. | Azole compounds |
AR040336A1 (es) | 2002-06-26 | 2005-03-30 | Glaxo Group Ltd | Compuesto de piperidina, uso del mismo para la fabricacion de un medicamento, composicion farmaceutica que lo comprende y procedimiento para preparar dicho compuesto |
AP1979A (en) * | 2002-09-20 | 2009-03-20 | Lupin Ltd | Pyrrole derivatives as antimycobacterial compounds |
US7135469B2 (en) | 2003-03-18 | 2006-11-14 | Bristol Myers Squibb, Co. | Linear chain substituted monocyclic and bicyclic derivatives as factor Xa inhibitors |
JPWO2004089954A1 (ja) | 2003-04-08 | 2006-07-06 | 大日本住友製薬株式会社 | 新規なカルバペネム化合物 |
DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
SE0302116D0 (sv) | 2003-07-21 | 2003-07-21 | Astrazeneca Ab | Novel compounds |
US7094791B2 (en) * | 2003-07-31 | 2006-08-22 | Avalon Pharmaceuticals, Inc. | Derivatives of 3-hydroxy-pyrrole-2,4-dicarboxylic acid and uses thereof |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
GB0325956D0 (en) | 2003-11-06 | 2003-12-10 | Addex Pharmaceuticals Sa | Novel compounds |
US20050197336A1 (en) * | 2004-03-08 | 2005-09-08 | Miikana Therapeutics Corporation | Inhibitors of histone deacetylase |
US7345043B2 (en) * | 2004-04-01 | 2008-03-18 | Miikana Therapeutics | Inhibitors of histone deacetylase |
EP1790636A4 (en) | 2004-09-17 | 2009-07-01 | Takeda Pharmaceutical | PIPERIDINE DERIVATIVES AND THEIR USE |
US7705042B2 (en) | 2004-10-22 | 2010-04-27 | Janssen Pharmaceutica Nv | Class of arylamide compounds useful as inhibitors of c-fms kinase |
AU2005299837A1 (en) | 2004-10-22 | 2006-05-04 | Janssen Pharmaceutica, N.V. | Inhibitors of c-fms kinase |
JP2008530192A (ja) | 2005-02-18 | 2008-08-07 | アストラゼネカ アクチボラグ | Dnaジャイレース及びトポイソメラーゼの阻害剤としてのピロール誘導体 |
WO2006087548A2 (en) | 2005-02-18 | 2006-08-24 | Astrazeneca Ab | Pyrrole derivatives as dna gyrase and topoisomerase inhibitors |
AU2006215399B2 (en) * | 2005-02-18 | 2010-12-09 | Astrazeneca Ab | Antibacterial piperidine derivatives |
EP1861396A1 (en) | 2005-03-04 | 2007-12-05 | AstraZeneca AB | Tricyclic derivatives of azetidine and pyrrole with antibacterial activity |
US20080269214A1 (en) | 2005-03-04 | 2008-10-30 | Astrazeneca Ab | Pyrrole Derivatives as Dna Gyrase and Topoisomerase Inhibitors |
US8071065B2 (en) * | 2005-03-31 | 2011-12-06 | Touchstone Research Laboratory, Ltd | High density carbon foam composite tooling |
WO2007071965A2 (en) | 2005-12-23 | 2007-06-28 | Astrazeneca Ab | Antibacterial pyrrolopyridines, pyrrolopyrimidines, and pyrroloazepines |
TW200819437A (en) | 2006-08-17 | 2008-05-01 | Astrazeneca Ab | Chemical compounds |
TW200906412A (en) * | 2007-06-12 | 2009-02-16 | Astrazeneca Ab | Piperidine compounds and uses thereof |
US8071605B2 (en) * | 2008-12-12 | 2011-12-06 | Astrazeneca Ab | Piperidine compounds for use in the treatment of bacterial infections |
-
2006
- 2006-02-16 AU AU2006215399A patent/AU2006215399B2/en not_active Ceased
- 2006-02-16 UA UAA200710264A patent/UA94901C2/ru unknown
- 2006-02-16 NZ NZ561613A patent/NZ561613A/en not_active IP Right Cessation
- 2006-02-16 JP JP2007514146A patent/JP4058106B2/ja not_active Expired - Fee Related
- 2006-02-16 KR KR1020137019849A patent/KR101422432B1/ko not_active IP Right Cessation
- 2006-02-16 CA CA2598423A patent/CA2598423C/en not_active Expired - Fee Related
- 2006-02-16 US US11/816,612 patent/US8399489B2/en not_active Expired - Fee Related
- 2006-02-16 MX MX2007010072A patent/MX2007010072A/es active IP Right Grant
- 2006-02-16 WO PCT/GB2006/000529 patent/WO2006087543A1/en active Application Filing
- 2006-02-16 EP EP06709766.7A patent/EP1853586B1/en active Active
- 2006-02-16 KR KR1020077021453A patent/KR20070113233A/ko not_active Application Discontinuation
- 2006-02-16 RU RU2007134380/04A patent/RU2424240C2/ru not_active IP Right Cessation
- 2006-02-16 CN CN2006800130583A patent/CN101163693B/zh not_active Expired - Fee Related
- 2006-02-16 ES ES06709766T patent/ES2430569T3/es active Active
- 2006-02-16 BR BRPI0607756-0A patent/BRPI0607756A2/pt not_active IP Right Cessation
- 2006-02-17 TW TW095105415A patent/TWI402263B/zh not_active IP Right Cessation
- 2006-02-17 UY UY29384A patent/UY29384A1/es not_active Application Discontinuation
- 2006-02-17 AR ARP060100590A patent/AR053683A1/es unknown
- 2006-02-18 SA SA6270020A patent/SA06270020B1/ar unknown
-
2007
- 2007-08-15 IL IL185306A patent/IL185306A/en not_active IP Right Cessation
- 2007-08-17 ZA ZA200706920A patent/ZA200706920B/xx unknown
- 2007-09-14 JP JP2007239467A patent/JP2008024715A/ja active Pending
- 2007-09-14 NO NO20074703A patent/NO20074703L/no not_active Application Discontinuation
- 2007-09-14 JP JP2007239383A patent/JP2007326882A/ja active Pending
- 2007-09-14 JP JP2007239427A patent/JP2007326883A/ja active Pending
-
2008
- 2008-03-07 HK HK08102716.1A patent/HK1114376A1/xx not_active IP Right Cessation
-
2013
- 2013-02-05 US US13/759,323 patent/US20130150366A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR053683A1 (es) | Derivados de piperidina con actividad antibacteriana | |
AR050545A1 (es) | Derivados de quinazolinonas y su uso como inhibidores de b-raf | |
AR063643A1 (es) | Compuestos quimicos derivados de quinolina, un metodo de preparacion y composiciones farmaceuticas | |
AR055249A1 (es) | Derivados de quinazolinas, procesos de obtencion y composiciones farmaceuticas | |
AR070493A1 (es) | Derivados heterociclicos de urea, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de infecciones bacterianas. | |
AR041594A1 (es) | Derivados de 1,4 piperidina disustituida y su uso como inhibidores de 11-beta hidroxiesteroide dehidrogenasa tipo 1 | |
AR056354A1 (es) | DERIVADOS DE PIRAZOL, UN MÉTODO DE PREPARACIoN DEL COMPUESTO, COMPOSICIoN FARMACÉUTICA Y PREPARACIoN DE UN MEDICAMENTO | |
AR056184A1 (es) | Compuestos derivados de pirazol, composicion farmaceutica en base a aquellos y su uso para la fabricacion de medicamentos | |
AR049662A1 (es) | Derivados de 1,3-fenilendiamina con efecto inhibitorio de b-raf; un metodo para su preparacion, composiciones farmaceuticas que los contienen y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer | |
AR056210A1 (es) | 4-(3-aminopirazol)pirimidina para uso como inhibidores de tirosina-quinasa | |
AR064130A1 (es) | Derivados de tiazoles y piridinas como antibacterianos. composiciones farmaceuticas. | |
AR054183A1 (es) | Derivados de piridincarboxamida y su uso como agentes anticancerigenos. procesos de obtencion y composiciones farmaceuticas. | |
AR066977A1 (es) | Compuestos de piperidina y usos de los mismos | |
AR047702A1 (es) | Imidazol-5-il-anilinopirimidinas como agentes inhibidores de la proliferacion celular | |
AR064208A1 (es) | Derivados de piridin-3-il-quinazolinas como inhibidores de b-raf. procesos de obtencion y composiciones farmaceuticas. | |
AR052170A1 (es) | Derivados de pirimidina utiles por su actividad anti-proliferacion celular | |
AR053992A1 (es) | Compuestos quimicos con actividad anticancerosa, un procedimiento para su preparacion, su uso en la preparacion de medicamentos y composicion farmaceutica. | |
AR046615A1 (es) | Pirrolidinas 3-(benzoil)-n-aciladas, como inhibidores de 11-beta-hsd1, utiles en el tratamiento de desordenes metabolicos | |
AR056556A1 (es) | Imidazo(1,2-a)piridina con actividad antiproliferacion celular | |
AR061653A1 (es) | Compuestos inhibidores de gsk3(glucogeno sintasa quinasa 3) | |
AR072046A1 (es) | Derivados de urea heterociclicos y sus metodos de uso | |
AR072047A1 (es) | Compuestos heterociclicos utiles para inhibir la adn girasa | |
AR033836A1 (es) | Compuesto 2-anilino-(imidazol-5-il)-pirimidina, composicion farmaceutica que lo comprende, su uso en la fabricacion de un medicamento que produce un efecto inhibitorio del ciclo celular y un proceso para su preparacion | |
AR040408A1 (es) | Derivados de benzotiadiazepina, procesos para su preparacion y composiciones farmaceuticas que los contienen | |
AR046616A1 (es) | Piperidinas sustituidas utiles en el tratamiento de sindrome metabolico |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |